4.6 Review

Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement

期刊

NEPHROLOGY DIALYSIS TRANSPLANTATION
卷 25, 期 12, 页码 3823-3831

出版社

OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfq513

关键词

calcium; chronic kidney disease mineral and bone disorder; colecalciferol; phosphate; vitamin D

资金

  1. Leo Pharmaceuticals
  2. Amgen
  3. Hoffman-Laroche
  4. Roche
  5. J+J
  6. Sandoz
  7. Shire
  8. Genzyme
  9. Merck
  10. Sanofi-Sythelabo
  11. Pfizer
  12. Bristol Myers Squibb
  13. Takeda
  14. Astellas

向作者/读者索取更多资源

Under the auspices of the European Renal Best Practice, a group of European nephrologists, not serving on the Kidney Disease Improving Global Outcomes (KDIGO) working group, but with significant clinical and research interests and expertise in these areas, was invited to examine and critique the Chronic Kidney Disease-Mineral and Bone Disorder KDIGO document published in August 2009. The final form of this paper in Nephrology Dialysis Transplantation, as a commentary, not as a position statement, reflects the fact that we have had no more evidence to review, discuss and debate available to us than was available to the KDIGO working group. However, we have felt that we were able to comment on specific areas where we feel that further clinical guidance would be helpful, thereby going beyond the KDIGO position as reflected in their document. This present paper, we hope, will be of most use to the practising kidney specialist and those allied to the clinical team.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据